MX2021013687A - Nuevas formas solidas de acido (2s,3s,4s,5r,6s)-3,4,5-trihidroxi-6 -(((4ar,10ar)-7-hidroxi-1-propil-1,2,3,4,4a,5,10,10a-octahidroben zo[g]quinolin-6-il)oxi)tetrahidro-2h-piran-2-carboxilico. - Google Patents

Nuevas formas solidas de acido (2s,3s,4s,5r,6s)-3,4,5-trihidroxi-6 -(((4ar,10ar)-7-hidroxi-1-propil-1,2,3,4,4a,5,10,10a-octahidroben zo[g]quinolin-6-il)oxi)tetrahidro-2h-piran-2-carboxilico.

Info

Publication number
MX2021013687A
MX2021013687A MX2021013687A MX2021013687A MX2021013687A MX 2021013687 A MX2021013687 A MX 2021013687A MX 2021013687 A MX2021013687 A MX 2021013687A MX 2021013687 A MX2021013687 A MX 2021013687A MX 2021013687 A MX2021013687 A MX 2021013687A
Authority
MX
Mexico
Prior art keywords
octahydrobenzo
trihydroxy
pyran
tetrahydro
oxy
Prior art date
Application number
MX2021013687A
Other languages
English (en)
Spanish (es)
Inventor
Morten Jørgensen
De Diego Heidi Lopez
Klaus Gjervig Jensen
Mikkel Fog Jacobsen
Frans Dennis Therkelsen
Martin Juhl
Lisbet Kværnø
Tobias Gylling Frihed
Karin Fredholt
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MX2021013687A publication Critical patent/MX2021013687A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MX2021013687A 2019-05-20 2020-05-19 Nuevas formas solidas de acido (2s,3s,4s,5r,6s)-3,4,5-trihidroxi-6 -(((4ar,10ar)-7-hidroxi-1-propil-1,2,3,4,4a,5,10,10a-octahidroben zo[g]quinolin-6-il)oxi)tetrahidro-2h-piran-2-carboxilico. MX2021013687A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201900599 2019-05-20
DKPA201900598 2019-05-20
DKPA201900612 2019-05-21
DKPA201900636 2019-05-24
PCT/EP2020/063910 WO2020234272A1 (en) 2019-05-20 2020-05-19 New solid forms of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar,10ar)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2h-pyran-2-carboxylic acid

Publications (1)

Publication Number Publication Date
MX2021013687A true MX2021013687A (es) 2021-12-10

Family

ID=70847349

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013687A MX2021013687A (es) 2019-05-20 2020-05-19 Nuevas formas solidas de acido (2s,3s,4s,5r,6s)-3,4,5-trihidroxi-6 -(((4ar,10ar)-7-hidroxi-1-propil-1,2,3,4,4a,5,10,10a-octahidroben zo[g]quinolin-6-il)oxi)tetrahidro-2h-piran-2-carboxilico.

Country Status (14)

Country Link
US (4) US11130775B2 (https=)
EP (1) EP3972969A1 (https=)
JP (3) JP7364691B2 (https=)
KR (1) KR102935865B1 (https=)
CN (1) CN113784965B (https=)
AU (1) AU2020280970B2 (https=)
BR (1) BR112021000833A2 (https=)
CA (1) CA3139784A1 (https=)
CL (1) CL2021002959A1 (https=)
IL (1) IL287954A (https=)
MX (1) MX2021013687A (https=)
SG (1) SG11202111874YA (https=)
WO (1) WO2020234272A1 (https=)
ZA (1) ZA202108768B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20200225A (es) 2017-11-24 2020-07-25 H Lundbeck As Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
JP7641234B2 (ja) * 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
WO2020234277A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
WO2020234276A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
IL316452A (en) 2022-04-25 2024-12-01 Integrative Res Laboratories Sweden Ab New esters of 1,2,3,4,4a,5,6,7,8,9,10,10a-dodecahydrobenzo[g]quinolin-6-ol compounds and their uses
WO2023208867A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF
US20250282733A1 (en) 2022-04-25 2025-09-11 Integrative Research Laboratories Sweden Ab Novel 1,2,3,4,4a,5,6,7,8,9,10,10a-dodecahydrobenzo[g]quinolin-6-ol compounds and uses thereof
WO2025078574A1 (en) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2025078571A1 (en) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL CARBONATES AND CARBAMATES OF 1,2,3,4,4a,5,6,7,8,9,10,10a- DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4543256A (en) 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
DE19575006I2 (de) 1981-10-16 2003-01-09 Novartis Ag 1, 2, 3, 4a, 5, 10, 10a-Octahydrobenzo(g)chinolin-Derivate mit pharmazeutischer Wirkung
FR2540112B1 (fr) 1983-02-01 1986-08-29 Sandoz Sa Nouveaux derives de la benzo(g)quinoleine, leur preparation et leur utilisation comme medicaments
JPS60172975A (ja) 1984-02-15 1985-09-06 Sumitomo Chem Co Ltd エリスロ−３−（３，４−メチレンジオキシフエニル）セリンの製造方法
GB2192394A (en) 1986-07-11 1988-01-13 Glaxo Group Ltd Amine derivatives
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
ES2070994T3 (es) 1989-04-20 1995-06-16 Zambon Spa Profarmaco de dopamina.
WO1990012574A1 (en) 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
IT1271411B (it) 1993-09-14 1997-05-28 Zambon Spa Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare
US5955468A (en) 1993-12-21 1999-09-21 Sandoz Ltd. Benzo G!quinolines for use in prevention or delay of progressive atrophy of the optic nerve
TW357143B (en) 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
IT1289979B1 (it) 1997-02-26 1998-10-19 Zambon Spa 5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari
US6410664B1 (en) 1997-03-24 2002-06-25 Cryovac, Inc. Catalyst compositions and processes for olefin polymers and copolymers
GB9902938D0 (en) 1999-02-10 1999-03-31 Novartis Ag Organic compounds
CO5261532A1 (es) 1999-11-15 2003-03-31 Novartis Ag Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
MXPA02009904A (es) 2000-04-07 2004-09-06 Tap Pharmaceutical Prod Inc Derivados de apomorfina y metodos para su uso.
SE0001438D0 (sv) 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
KR20030027020A (ko) 2000-08-11 2003-04-03 펄듀 리서치 파운데이션 디나프솔린의 제조 공정
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
SE0002934D0 (sv) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
PE20030240A1 (es) 2001-07-09 2003-04-16 Novartis Ag DERIVADOS DE BENZO [g] QUINOLINA
DE60220800D1 (de) 2001-08-10 2007-08-02 Purdue Research Foundation Chirales dinapsolin
EG24415A (en) 2002-03-07 2009-05-25 Novartis Ag Quinoline derivatives
CA2479372A1 (en) 2002-03-19 2003-10-02 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
US20070155720A1 (en) 2003-12-23 2007-07-05 Darpharma, Inc. Co-administration of dopamine-receptor binding compounds
US7648995B2 (en) 2004-04-13 2010-01-19 The Mclean Hospital Corporation R(—)-11-hydroxyaporphine derivatives and uses thereof
WO2006012640A2 (en) 2004-07-21 2006-02-02 Darpharma, Inc. Method of administration of dopamine receptor agonists
WO2006056604A1 (en) 2004-11-25 2006-06-01 Evolva Ag Levodopa glycosyl derivatives, methods of preparation and use
CN1828649A (zh) * 2005-12-22 2006-09-06 韩燕� 一种电子支付认证的方法及其id鉴别终端与atm
US20090124651A1 (en) 2007-08-31 2009-05-14 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
CN102131790A (zh) 2008-06-27 2011-07-20 H.隆德贝克有限公司 新型苯酚型和儿茶酚型胺及其前药
TW201036949A (en) 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
TW201035054A (en) 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
EP2557079A1 (en) 2011-08-09 2013-02-13 Nestec S.A. Synthesis of catechin and epicatechin conjugates
DE102011112496A1 (de) 2011-09-07 2013-03-07 Thanares GmbH 4-Methylcatecholderivate und deren Verwendung
CN102746351B (zh) 2012-07-23 2018-03-02 上海弈柯莱生物医药科技有限公司 灯盏花乙素及其类似物的制备方法
GB201319768D0 (en) 2013-11-08 2013-12-25 Glycosynth Ltd Naphthalene derived chromogenic enzyme substrates
RU2021103000A (ru) 2014-10-21 2021-03-01 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
CN105218606B (zh) 2015-10-19 2017-12-01 昆明理工大学 一种制备灯盏乙素的方法
EP4295909A3 (en) 2016-04-20 2024-07-17 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
US9920342B2 (en) 2016-05-17 2018-03-20 Divi's Laboratories Limited Process for the preparation of Droxidopa
CR20200225A (es) 2017-11-24 2020-07-25 H Lundbeck As Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
WO2020234276A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
WO2020234277A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
JP7641234B2 (ja) 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
EP4247793A1 (en) 2020-11-17 2023-09-27 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease

Also Published As

Publication number Publication date
SG11202111874YA (en) 2021-12-30
US11858954B2 (en) 2024-01-02
CN113784965B (zh) 2024-05-03
EP3972969A1 (en) 2022-03-30
US11130775B2 (en) 2021-09-28
WO2020234272A1 (en) 2020-11-26
KR102935865B1 (ko) 2026-03-05
US20220024962A1 (en) 2022-01-27
CN113784965A (zh) 2021-12-10
JP2023179408A (ja) 2023-12-19
IL287954A (en) 2022-01-01
KR20220010485A (ko) 2022-01-25
CL2021002959A1 (es) 2022-08-19
US20200392176A1 (en) 2020-12-17
BR112021000833A2 (pt) 2021-04-13
US12421271B2 (en) 2025-09-23
AU2020280970B2 (en) 2025-08-07
US20260055131A1 (en) 2026-02-26
JP2022533050A (ja) 2022-07-21
AU2020280970A1 (en) 2021-12-09
JP7364691B2 (ja) 2023-10-18
JP7620677B2 (ja) 2025-01-23
JP2025063149A (ja) 2025-04-15
US20240190909A1 (en) 2024-06-13
ZA202108768B (en) 2023-07-26
CA3139784A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
MX2021013687A (es) Nuevas formas solidas de acido (2s,3s,4s,5r,6s)-3,4,5-trihidroxi-6 -(((4ar,10ar)-7-hidroxi-1-propil-1,2,3,4,4a,5,10,10a-octahidroben zo[g]quinolin-6-il)oxi)tetrahidro-2h-piran-2-carboxilico.
CL2021002775A1 (es) Un procedimiento para la fabricación de ácido(2s,3s,4s,5r,6s)-3,4,5-trihidroxi-6-(((4ar,10ar)-7-hidroxi-1-propil-1,2,3,4,4a,5, 10,10a-octahidrobenzo[g]quinolin-6-il)oxi)tetrahidro-2h-piran-2-acido carboxílico y sus intermedios.
MX2021013425A (es) Un procedimiento para la fabricacion de acido (2s,3s,4s,5r,6s)-3,4,5-trihidroxi-6-(((4ar,10ar)-7-hidroxi-1-prop il-1,2,3,4,4a,5,10,10a-octahidrobenzo[g]quinolin-6-il)oxi)tetrahi dro-2h-piran-2-carboxilico.
AR123407A1 (es) Un proceso para la fabricación de (6ar,10ar)-7-propil-6,6a,7,8,9,10,10a,11-octahidro-[1,3]dioxolo[4’,5’:5,6]benzo[1,2-g]quinolina y (4ar,10ar)-1-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolina-6,7-diol
CY1124130T1 (el) Παραγωγο 2.2-διφθοροπροπιοναμιδιου απο μεθυλικη βαρδοξολονη, φαρμακευτικες συνθεσεις και πολυμορφικες μορφες τους για χρηση στη θεραπευτικη αντιμετωπιση συγκεκριμενων παθησεων
PE20211290A1 (es) Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad del parkinson
MX382599B (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina.
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.
DOP2013000194A (es) Imidazo[5,1-f][1,2,4] triazinas para el tratamiento de trastornos neurologicos
CO6480975A2 (es) Mimetico de smac
CR9485A (es) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
ECSP066730A (es) Compuestos y procedimientos para uso
CL2015000096A1 (es) Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros
CR20180452A (es) Moduladores alostéricos de receptores de acetilcolina nicotícos
CL2011002382A1 (es) Uso de un compuesto derivado de quinazolina-2,4-diona para el tratamiento y/o la prevencion de trastornos asociados al sistema nervioso central y/o al sistema nervioso periferico, preferentemente trastornos asociados a esquizofrenia, enfermedad de parkinson y enfermedad de alzheimer.
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
BR112022010181A2 (pt) Composto tri-heterocíclico como inibidor de jak e uso do mesmo
AR041937A1 (es) Proceso para la preparacion de derivados de carboestirilo
WO2013181202A3 (en) Chromane compounds
BR112014010584A2 (pt) métodos de tratamento de doenças e distúrbios relacionados à atividade da proteína 1 (tbl1) beta-similar a transducina, incluindo neoplasia mieloproliferativa e leucemia mieloide crônica
CO2020009761A2 (es) Formas de co-cristales de un análogo de novobiocina y prolina
ECSP10010571A (es) SINTESIS DE DIHIDROTIENO[3,2-d]PIRIMIDINA-DIOLES Y PIRIMIDINA-DIOLES SIMILARES
BR112014000473A2 (pt) processo para a preparação de 2-amino-5-ciano-n,3-dimetilbenzamida
WO2013167986A3 (en) Compositions and methods for the treatment of epilepsy